Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 1, 2013, Pages 39-44

  Greener, Benjamin N ^a   Patterson, Kristine B ^b   Prince, Heather M A ^b   Sykes, Craig S ^a   Adams, Jessica L ^a   Dumond, Julie B ^a   Shaheen, Nicholas J ^b   Madanick, Ryan D ^b   Dellon, Evan S ^b   Cohen, Myron S ^b   Kashuba, Angela D M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal tissue; Dolutegravir S GSK1349572; Integrase inhibitor; Male genital tract; Seminal fluid

Indexed keywords

DOLUTEGRAVIR;

ADULT; ARTICLE; COLON; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MALE GENITAL SYSTEM; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM; RECTUM MUCOSA; SEMINAL PLASMA; TANDEM MASS SPECTROMETRY; VIRUS INHIBITION;

ADULT; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; RECTUM; SEMEN; TREATMENT OUTCOME;

EID: 84883385762     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829ed7a4     Document Type: Article

References (20)

1. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258
2. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737-1745
3. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter-and intra-patient variability of raltegravir pharmacokinetics in HIV-1 infected subjects. J Antimicrob Chemother. 2012;67:460-464
4. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-743
5. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5
6. Zuckerman RA, Whittington WL, Celum CL, et al. Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis. 2004;190:156-161
7. Lorello G, la Porte C, Pilon R, et al. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009;10:548-554
8. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202:1553-1561
9. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS. 2000;14:F69-F75
10. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort. AIDS. 2000;14:117-121
11. Bujan L, Daudin M, Matsuda T, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS. 2004;18:757-766
12. Poles MA, Boscardin WJ, Elliott J, et al. Lack of decay of HIV-1 in gutassociated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr. 2006;43:65-68
13. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929
14. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505
15. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88:598-609
16. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. US Department of Health and Human Services, December 28, 2004, with clarification August 2009. Available at: Http://rsc.tech-res. com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity- of-Adult-Pediatric-Adverse-Events.pdf
17. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627-1629
18. Brown KC, Patterson KB, Jennings SH, et al. Single and multiple dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr. 2012; 61:138-144
19. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203:1484-1490
20. Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: Implications for eradication and cure. AIDS. 2013;27:1413-1419